Table 1.
Results of mutation detection
| No metastases | Synchronous metastases | Metachronous metastases | ||||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| Number | % | Number | % | Number | % | |
| Total patients (n) | 96 | - | 92 | - | 93 | - |
| All WT | 46 | 47.9 | 27 | 29.3 | 30 | 32.3 |
| Total KRAS MT | 28 | 29.2 | 43 | 46.7 | 44 | 47.3 |
| Total KRAS 12 MT | 24 | 25.0 | 36 | 39.1 | 23 | 24.7 |
| Total KRAS 13 MT | 4 | 4.2 | 7 | 7.6 | 21 | 22.6 |
| Total BRAF MT | 4 | 4.2 | 12 | 13.0 | 2 | 2.2 |
| RAS-RAF-MAPK MT | 32 | 33.3 | 55 | 59.8 | 46 | 49.5 |
| Total PIK3CA MT | 13 | 13.5 | 20 | 21.7 | 15 | 16.1 |
| Total PTEN MT | 15 | 15.6 | 14 | 15.2 | 17 | 18.3 |
| PI3K-PTEN-AKT MT | 26 | 27.1 | 33 | 35.9 | 28 | 30.1 |
| Only KRAS 12 MT | 19 | 19.8 | 20 | 21.7 | 15 | 16.1 |
| Only KRAS 13 MT | 2 | 2.1 | 4 | 4.3 | 18 | 19.4 |
| Only BRAF MT | 3 | 3.1 | 11 | 12.0 | 2 | 2.2 |
| Only PIK3CA MT | 7 | 7.3 | 5 | 5.4 | 7 | 7.5 |
| Only PTEN MT | 10 | 10.4 | 5 | 5.4 | 7 | 7.5 |
| Only KRAS + PIK3CA MT | 3 | 3.1 | 12 | 13.0 | 4 | 4.3 |
| Only KRAS 12 + PIK3CA MT | 2 | 2.1 | 8 | 8.7 | 2 | 2.2 |
| Only KRAS 13 + PIK3CA MT | 1 | 1.0 | 2 | 2.2 | 2 | 2.2 |
| Only KRAS + PTEN MT | 3 | 3.1 | 6 | 6.5 | 6 | 6.5 |
| Only KRAS 12 + PTEN MT | 2 | 2.1 | 6 | 6.5 | 6 | 6.5 |
| Only KRAS 13 + PTEN MT | 1 | 1.0 | 0 | 0.0 | 0 | 0.0 |
| KRAS + PIK3CA + PTEN MT | 1 | 1.0 | 2 | 2.2 | 1 | 1.1 |
| Only BRAF + PIK3CA MT | 1 | 1.0 | 1 | 1.1 | 0 | 0.0 |
| Only BRAF + PTEN MT | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Only PIK3CA + PTEN MT | 1 | 1.0 | 0 | 0.0 | 3 | 3.2 |
WT: wild type; MT: mutant type; Total: patients with at least one gene mutation; Only: patients without other gene mutations. RAS-RAF-MAPK MT: patients with any of KRAS or BRAF mutation. PI3K-PTEN-AKT MT: patients with any of PIK3CA or PTEN mutation.